FIELD: pharmaceutics.
SUBSTANCE: invention relates to an oral solid dosage form for inhibiting tyrosine kinase Abl, containing a mixture of a compound of Formula I
Formula I and a fusible polymer carrier; where the fusible polymer carrier is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer; and where said mixture is an amorphous dispersion obtained by hot melt extrusion.
EFFECT: what is prepared is an oral solid dosage form for inhibiting tyrosine kinase Abl, which has improved bioavailability and stability.
4 cl, 4 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW AMORPHOUS DISPERSION OF N'-(2-CHLOR-6-METHYL-BENZOYL)HYDRAZIDE OF 4-METHYL-3-QUINOLINE-3-YLETHYNYL-BENZOIC ACID | 2018 |
|
RU2777569C2 |
| POLYMORPHOUS AND AMORPHOUS FORMS OF {2-FLUORINE-5-[3-((E)-2-PYRIDINE-2-ILVINYL)-1N-INDAZOLE-6-ILAMINE]PHENYL}AMIDE 2, 5-DIMETHYL-2N-PYRAZOLE-3-CARBONIC ACID | 2005 |
|
RU2324692C1 |
| TOSYLATE SALT OF 5-PYRAZOLYL-2-PYRIDONE DERIVATIVE EFFECTIVE IN COPD TREATMENT | 2010 |
|
RU2526038C2 |
| COMPOSITION OF NANOSTRUCTURED APREPITANT, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2011 |
|
RU2595841C2 |
| MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND THEIR CRYSTAL FORM | 2012 |
|
RU2621719C2 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
| POLYMORPHOUS AND AMORPHOUS FORMS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINE[5,4,3-CD]INDOL-6-ON PHOSPHATE | 2005 |
|
RU2355691C2 |
| -N-{4-[3-CHLOR-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE MALEATE SALTS AND THEIR CRYSTALLINE FORMS | 2008 |
|
RU2463300C2 |
| NEW CRYSTALLINE FORMS | 2007 |
|
RU2446156C2 |
| SOLID DISPERSIONS | 2016 |
|
RU2694832C2 |
